Data Exchange. [[3D Medicines:Organization]] shall keep [[Aravive:Organization]] reasonably informed of [[3D Medicines:Organization]]’, its Affiliates’ and their respective Sublicensees’ Commercialization activities with respect to the Licensed Products in the Field in the [[3D Medicines:Organization]] Territory. [[Aravive:Organization]] shall provide to [[3D Medicines:Organization]], upon [[3D Medicines:Organization]]’ request, and no more than once each Calendar Quarter, at [[Aravive:Organization]]’s cost, copies of any materials prepared by or on behalf of [[Aravive:Organization]] that are necessary or reasonably useful in connection with [[3D Medicines:Organization]]’ Commercialization of Licensed Products in the Field in the [[3D Medicines:Organization]] Territory (including relevant training materials, global brand and global market research, in each case, with respect to Licensed Products), and, to the extent elected by [[3D Medicines:Organization]], [[3D Medicines:Organization]] shall have the right to use such materials in connection with the Commercialization of Licensed Products in the Field in the [[3D Medicines:Organization]] Territory in accordance with the Agreement.

In addition to [[GlycoMimetics:Organization]]’ obligation with respect to the transfer of [[GlycoMimetics:Organization]] Licensed Know-How set forth under Section 2.6 and each Party’s adverse event and safety data reporting obligations pursuant to Section 5.8, but subject to the remainder of this Section 4.7, each Party shall, at its sole cost and expense, promptly provide the other Party with copies of all Data and access to Regulatory Materials related to all Licensed Products generated by or on behalf of such Party or its Affiliates or sublicensees in the performance of Development activities of the Licensed Products in their respective territories (the “Product Materials”). The JDC may establish reasonable policies to effectuate such exchange of Product Materials between the Parties. For clarity, [[GlycoMimetics:Organization]] shall not be obligated to share with Apollomics or provide Apollomics access to CMC Information or any other Information related to the Manufacture of Licensed Products (except as set forth in Sections 5.1 and 7.2).

Safety Data Exchange. The Parties will negotiate in good faith promptly following the Effective Date a safety data exchange agreement regarding Product, which will set forth standard operating procedures governing the collection, investigation, reporting and exchange of information concerning adverse drug reactions/experiences sufficient to permit each Party to comply with its regulatory and other legal obligations within the applicable timeframes (the “Pharmacovigilance Agreement”). The Pharmacovigilance Agreement will # identify which Party will be responsible for the timely reporting of all relevant adverse drug reactions/experiences, Product complaints and safety data relating to Product to the appropriate Regulatory Authorities in both the Relief Territory and the Acer Territory in accordance with all Applicable Laws and # allow each Party to comply with all regulatory and legal requirements regarding the management of safety data by providing for the exchange of relevant information in the appropriate format within applicable timeframes.

Data Exchange. During the Term, and subject to Applicable Laws and good scientific practice, each Party shall provide to the other Party promptly upon reasonable request by such other Party to the extent not already provided and at no additional cost to such other Party, electronic access to all Data generated by or on behalf of the Party, its Affiliates or Sublicensees (and with respect to [[Forty Seven:Organization]] Partners, Data generated by or on behalf of a [[Forty Seven:Organization]] Partner from any Global Study or which a [[Forty Seven:Organization]] Partner has agreed to provide to Ono in accordance with [Section 4.4.3]) with respect to and in the course of conducting studies with respect to the Products (including all study reports analyzing such Data), which are necessary or reasonably useful for such other Party to obtain or maintain Regulatory Approval of such Products in its respective Territory. For clarity, neither Party shall have any obligation to provide any Data Execution Version

Safety Data Exchange. Within ​ of the Effective Date, but in any event prior to commencement of any Clinical Trials with respect to the Product in the Territory, the Parties will in good faith negotiate and execute a separate safety data exchange agreement (the “Pharmacovigilance Agreement”), the terms of which shall set forth the obligations, procedures and timelines for MTPC to report information (such as the occurrence of Adverse Events and serious Adverse Events) observed in connection with the Product in order to enable Viela to comply with its safety reporting obligations to Regulatory Authorities in and outside the Territory. Prior to the execution of the Pharmacovigilance Agreement, MTPC shall promptly notify Viela of any information observed in connection with the Product that MTPC reasonably determines to be necessary to enable Viela to comply with its safety reporting obligations to Regulatory Authorities in and outside the Territory. Any serious Adverse Events shall be reported to Viela within ​ after MTPC becomes aware of their occurrence. Viela shall maintain the global safety database for the Product, which shall include Adverse Events and other information relating to the safety of the Product. Upon reasonable advanced request by MTPC, Viela shall make the data maintained in the global safety database accessible and available to MTPC in the form in which such data is then-currently maintained by Viela.

Data Exchange. Apollomics shall keep [[GlycoMimetics:Organization]] reasonably informed of Apollomics’, its Affiliates’ and their respective sublicensees’ Commercialization activities with respect to the Licensed Products in the Field in the Apollomics Territory. [[GlycoMimetics:Organization]] shall provide and/or disclose to Apollomics, upon Apollomics’ request, and no more than once each Calendar Quarter, at [[GlycoMimetics:Organization]]’ cost, copies of any materials prepared by or on behalf of [[GlycoMimetics:Organization]] that are necessary or reasonably useful in connection with Apollomics’ Commercialization of Licensed Products in the Field in the Apollomics Territory (including relevant training materials, global brand and global market research, in each case, with respect to Licensed Products).

Data Exchange. In addition to [[Aravive:Organization]]’s obligation with respect to the transfer of [[Aravive:Organization]] Licensed Know-How set forth under Section 2.6 and each Party’s adverse event and safety Data reporting obligations pursuant to [Section 5.8], but subject to any applicable Laws and the remainder of this [Section 4.6], each Party shall, at its sole cost and expense, promptly provide the other Party with copies of any Data and Regulatory Materials related to the Licensed Compound or Licensed Products generated by or on behalf of such Party or its Affiliates or Sublicensees in the performance of Development activities hereunder that would be reasonably necessary for the Development, Manufacture and Commercialization of Licensed Compound or Licensed Products in the Field in the other Party’s respective territory (the “Product Materials”). The JSC may establish reasonable policies to effectuate the exchange of additional Product Materials between the Parties. For clarity, [[Aravive:Organization]] shall not be obligated under this [Section 4.6] to share with [[3D Medicines:Organization]] or provide [[3D Medicines:Organization]] access to CMC Information or any other Information related to the Manufacture of Licensed Products (which, for clarity, will be transferred under [Sections 7.1(b) and 7.2(b)])]).

Data Exchange. Each Party shall, at its own cost, reasonably cooperate with the other to effectively share and exchange data in relation to Commercialization activities under this Agreement in accordance with the terms set forth in the attached [Schedule C].

Exchange of Development Data. Without limiting the other provisions of this Agreement, at the request of a Party or upon direction by the JSC or JDC, the other Party shall provide to the requesting Party all pertinent Data developed by or on behalf of such Party, as applicable, in connection with the Development of a Licensed Product under this Agreement or the performance of other activities under the Global Development Plan or Commercialization Plans hereunder subject to any applicable confidentiality arrangements with Third Parties ​. The format of, and media for exchanging, such Data shall be decided by the JDC.

. Upon request from either Party and in connection with the potential Exploitation of Licensed Product in the Retained Territory, the Parties shall negotiate in good faith, or [[DURECT:Organization]] shall use ​ to facilitate a negotiation between INNOCOLL and a Third Party Licensee to enter into, a data exchange agreement on reasonable and customary terms for the Parties (or INNOCOLL and such Third Party Licensee) to exchange their respective Data concerning Licensed Products obtained in their respective Territories (“Data Exchange Agreement”).